<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180271</url>
  </required_header>
  <id_info>
    <org_study_id>Clinicals0003</org_study_id>
    <secondary_id>MADIT-CRT</secondary_id>
    <nct_id>NCT00180271</nct_id>
  </id_info>
  <brief_title>MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy</brief_title>
  <acronym>MADIT-CRT</acronym>
  <official_title>Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MADIT-CRT trial is designed to determine if combined implantable cardiac defibrillator
      (ICD)-cardiac resynchronization therapy (CRT-D) will reduce the risk of mortality and heart
      failure (HF) events by approximately 25%, in subjects who are in New York Heart Association
      (NYHA) functional Class II with non-ischemic or ischemic cardiomyopathy and subjects who are
      in NYHA functional Class I with ischemic cardiomyopathy, left ventricular dysfunction
      (ejection fraction [EF] &lt; or = 0.30), and prolonged intraventricular conduction (QRS duration
      &gt; or = 130 ms).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, subjects will be randomized to CRT-D or ICD-only. Randomization will be
      stratified by clinical center and ischemic status. Approximately 60% of the subjects will be
      randomly assigned to receive a CRT-D with biventricular pacing, and 40% will receive an ICD
      only. Optimal pharmacological therapy for heart failure will be required in both treatment
      arms. Length of follow-up for each subject will depend on the date of entry into the study,
      since all subjects will be followed to a common study termination date.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality From Any Cause or First Heart Failure (HF) Event</measure>
    <time_frame>Outcome measured at average follow-up duration of 2.4 years.</time_frame>
    <description>MADIT-CRT was an event-driven trial in which patients were monitored for all-cause mortality and HF events. An HF event was defined as either hospitalization for symptoms and/or signs consistent with congestive HF and:
administration of intravenous decongestive therapy that does not involve formal in-patient hospital admission, regardless of the setting (i.e. in an emergency room setting, in the physician's office, etc.), or
administration of an augmented HF regimen with oral or intravenous medications during an in-hospital stay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent Heart Failure Events</measure>
    <time_frame>Time of event, DSMB review</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1820</enrollment>
  <condition>Tachycardia</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>CRT-D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRT-D: Cardiac resynchronization therapy with defibrillation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ICD: Implantable cardioverter defibrillator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac resynchronization therapy with defibrillation</intervention_name>
    <description>Boston Scientific Corporation Market Released Cardiac Resynchronization therapy with defibrillation</description>
    <arm_group_label>CRT-D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Cardioverter Defibrillator (ICD)</intervention_name>
    <description>Boston Scientific Corporation Market Released Implantable Cardioverter Defibrillator</description>
    <arm_group_label>ICD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic heart disease defined as:

               -  NYHA Class I or II for the past 3 calendar months prior to, and at the time of,
                  enrollment;

               -  one or more clinically documented (Q wave or enzyme positive) prior myocardial
                  infarctions, but not within 3 calendar months of enrollment; and/or

               -  one or more prior coronary artery bypass graft surgeries or percutaneous coronary
                  interventions (balloon and/or stent angioplasty) but not within 3 calendar months
                  of enrollment.

        OR

          -  Non-ischemic heart disease including dilated cardiomyopathy characterized by a low
             ejection fraction and increased ventricular volume, with ventricular compliance that
             is normal or increased

          -  NYHA Class II for the past 3 calendar months prior to, and at the time of, enrollment

        AND all of the following:

          -  Stable optimal pharmacologic therapy.

          -  An ejection fraction &lt; or = 0.30 by angiographic, radionuclide, or echocardiographic
             methods within one year prior to enrollment and measured during the enrollment
             echocardiogram obtained within 14 days prior to randomization to confirm eligibility
             (recommended)

          -  Resting QRS duration &gt; or = 130 ms on print-out of a current electrocardiogram (ECG)
             obtained within 14 days prior to randomization.

          -  Sinus rhythm by ECG (including right bundle branch block [RBBB] and first degree heart
             block with PR &lt; 250 ms.)

          -  Men and women 21 years of age or older (no upper-age cut off)

        Exclusion Criteria:

          -  Existing indication for CRT

          -  Subjects with an implanted pacemaker

          -  Subjects with an existing ICD or CRT device

          -  Subjects in NYHA Class I with non-ischemic cardiomyopathy

          -  Subjects in NYHA Class III or IV in the past 3 calendar months prior to, or at the
             time of, enrollment

          -  Coronary artery bypass graft surgery or percutaneous coronary intervention (balloon
             and/or stent angioplasty) within the past 3 calendar months prior to enrollment

          -  Enzyme-positive myocardial infarction within the past 3 calendar months prior to
             enrollment

          -  Subjects with angiographic evidence of coronary disease who are candidates for
             coronary revascularization and are likely to undergo coronary artery bypass graft
             surgery or percutaneous coronary intervention in the foreseeable future

          -  Subjects with second or third degree heart block

          -  Subjects with irreversible brain damage from preexisting cerebral disease

          -  Women who are pregnant or plan to become pregnant during the course of the trial.
             Women of childbearing potential must have a negative pregnancy test within 7 days
             prior to enrollment.

          -  Reversible non-ischemic cardiomyopathy such as acute viral myocarditis or
             discontinuation of alcohol in alcohol-induced heart disease

          -  Subjects with chronic atrial fibrillation within one month prior to enrollment

          -  Presence of any disease, other than the subject's cardiac disease, associated with a
             reduced likelihood of survival for the duration of the trial, e.g., cancer, uremia
             (blood urea nitrogen [BUN] &gt; 70 mg/dl or creatinine &gt; 3.0 mg/dl), liver failure, etc.

          -  Subjects participating in any other clinical trials

          -  Subjects unwilling or unable to cooperate with the protocol

          -  Subjects who live at such a distance from the clinic that travel for follow-up visits
             would be unusually difficult

          -  Subjects who do not anticipate being residents of the area for the scheduled duration
             of the trial

          -  Subjects unwilling to sign the consent for participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur Moss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Multiple locations in the US and international</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>February 23, 2011</results_first_submitted>
  <results_first_submitted_qc>May 31, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2011</results_first_posted>
  <disposition_first_submitted>July 9, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>July 12, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 14, 2010</disposition_first_posted>
  <last_update_submitted>January 24, 2012</last_update_submitted>
  <last_update_submitted_qc>January 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Defibrillator</keyword>
  <keyword>Cardiac Resynchronization Therapy</keyword>
  <keyword>MADIT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study enrolled 1820 patients from 110 hospital centers (88 in the United States, 2 in Canada, and 20 in Europe) between December 22, 2004 and April 23, 2008. Follow-up continued thereafter until trial termination.</recruitment_details>
      <pre_assignment_details>Data from all patients enrolled were analyzed on an intention-to-treat basis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cardiac Resynchronization Therapy + Defibrillator</title>
          <description>Patients randomized to cardiac resynchronization therapy with backup defibrillation (CRT-D) in addition to optimal pharmacologic therapy (as administered by the primary care physician). CRT-D devices both deliver shocks to terminate potentially lethal ventricular arrhythmias and pace both ventricles in patients with ventricular dyssynchrony.</description>
        </group>
        <group group_id="P2">
          <title>Implantable Cardioverter Defibrillator Alone</title>
          <description>Patients randomized to implantable cardioverter defibrillator (ICD) in addition to optimal pharmacologic therapy (as administered by the primary care physician). ICDs deliver shocks to terminate potentially lethal ventricular arrhythmias.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1089"/>
                <participants group_id="P2" count="731"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1089"/>
                <participants group_id="P2" count="731"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cardiac Resynchronization Therapy + Defibrillator</title>
          <description>Patients randomized to cardiac resynchronization therapy with backup defibrillation (CRT-D) in addition to optimal pharmacologic therapy (as administered by the primary care physician). CRT-D devices both deliver shocks to terminate potentially lethal ventricular arrhythmias and pace both ventricles in patients with ventricular dyssynchrony.</description>
        </group>
        <group group_id="B2">
          <title>Implantable Cardioverter Defibrillator Alone</title>
          <description>Patients randomized to implantable cardioverter defibrillator (ICD) in addition to optimal pharmacologic therapy (as administered by the primary care physician). ICDs deliver shocks to terminate potentially lethal ventricular arrhythmias.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1089"/>
            <count group_id="B2" value="731"/>
            <count group_id="B3" value="1820"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="543"/>
                    <measurement group_id="B2" value="380"/>
                    <measurement group_id="B3" value="923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="546"/>
                    <measurement group_id="B2" value="351"/>
                    <measurement group_id="B3" value="897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="11"/>
                    <measurement group_id="B2" value="64" spread="11"/>
                    <measurement group_id="B3" value="65" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="814"/>
                    <measurement group_id="B2" value="553"/>
                    <measurement group_id="B3" value="1367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="757"/>
                    <measurement group_id="B2" value="514"/>
                    <measurement group_id="B3" value="1271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mortality From Any Cause or First Heart Failure (HF) Event</title>
        <description>MADIT-CRT was an event-driven trial in which patients were monitored for all-cause mortality and HF events. An HF event was defined as either hospitalization for symptoms and/or signs consistent with congestive HF and:
administration of intravenous decongestive therapy that does not involve formal in-patient hospital admission, regardless of the setting (i.e. in an emergency room setting, in the physician’s office, etc.), or
administration of an augmented HF regimen with oral or intravenous medications during an in-hospital stay.</description>
        <time_frame>Outcome measured at average follow-up duration of 2.4 years.</time_frame>
        <population>Analysis was performed on an intention-to-treat basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cardiac Resynchronization Therapy + Defibrillator</title>
            <description>Patients randomized to cardiac resynchronization therapy with backup defibrillation (CRT-D) in addition to optimal pharmacologic therapy (as administered by the primary care physician). CRT-D devices both deliver shocks to terminate potentially lethal ventricular arrhythmias and pace both ventricles in patients with ventricular dyssynchrony.</description>
          </group>
          <group group_id="O2">
            <title>Implantable Cardioverter Defibrillator Alone</title>
            <description>Patients randomized to implantable cardioverter defibrillator (ICD) in addition to optimal pharmacologic therapy (as administered by the primary care physician). ICDs deliver shocks to terminate potentially lethal ventricular arrhythmias.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality From Any Cause or First Heart Failure (HF) Event</title>
          <description>MADIT-CRT was an event-driven trial in which patients were monitored for all-cause mortality and HF events. An HF event was defined as either hospitalization for symptoms and/or signs consistent with congestive HF and:
administration of intravenous decongestive therapy that does not involve formal in-patient hospital admission, regardless of the setting (i.e. in an emergency room setting, in the physician’s office, etc.), or
administration of an augmented HF regimen with oral or intravenous medications during an in-hospital stay.</description>
          <population>Analysis was performed on an intention-to-treat basis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="731"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients who are Event Free</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="902"/>
                    <measurement group_id="O2" value="546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Death or Heart Failure Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Heart Failure Event Alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Death at Any Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The trial utilized a Wang-Tsiatis (delta=0.1) group-sequential design with 95% power to detect a hazard ratio of 0.75 at a two-sided significance level of 0.05. Primary analysis was based on statistical evaluation comparing the life-table event-free survival time graphs for CRT-D and ICD-only arms of the trial. Stratified Cox proportional-hazards regression was used to estimate a hazard ratio and statistical significance was evaluated with the log-rank test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>The trial involved prespecified event monitoring at up to 20 successive periods by an independent DSMB to permit trial termination if the CRT-D was superior to, inferior to, or not different from ICD according to prespecified stopping rules.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
            <estimate_desc>A Hazard ratio &lt; 1.0 would indicate that the result favors CRT-D.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Heart Failure Events</title>
        <time_frame>Time of event, DSMB review</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>91 Days</time_frame>
      <desc>The primary outcome was performed on an intention-to-treat basis and all participants were followed. However, the number of participants at risk for adverse events is fewer than the total number in the primary outcome. Some participants did not undergo the surgical procedure for device implant and were therefore not subjected to risk.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cardiac Resynchronization Therapy + Defibrillator</title>
          <description>Patients randomized to cardiac resynchronization therapy with backup defibrillation (CRT-D) in addition to optimal pharmacologic therapy (as administered by the primary care physician). CRT-D devices both deliver shocks to terminate potentially lethal ventricular arrhythmias and pace both ventricles in patients with ventricular dyssynchrony.</description>
        </group>
        <group group_id="E2">
          <title>Implantable Cardioverter Defibrillator Alone</title>
          <description>Patients randomized to implantable cardioverter defibrillator (ICD) in addition to optimal pharmacologic therapy (as administered by the primary care physician). ICDs deliver shocks to terminate potentially lethal ventricular arrhythmias.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="1079"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="712"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic Events</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1079"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="712"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Lead Dislodgment, Left Ventricular</sub_title>
                <counts group_id="E1" events="51" subjects_affected="46" subjects_at_risk="1079"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Lead Dislodgment, Right Atrial</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="1079"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Extracardiac Stimulation, Left Ventricular</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Lead Dislodgment, Right Ventricular</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1079"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Elevated Threshold, Right Ventricular</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1079"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Inadvertent Ventricular Tachyarrhythmia</sub_title>
                <description>Arrhythmia inadvertently induced during implant procedure.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1079"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Elevated Defibrillation Thresholds</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1079"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Inappropriate Tachyarrhythmia Therapy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1079"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Early Elective Replacement Indicator</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1079"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Insulation Breach, Left Ventricular Lead</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Inadvertent Supraventricular Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Worsening Heart Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1079"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Elevated Threshold, Left Ventricular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Difficulty Measing Impedance/Amplitude</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Elevated Shock Impedance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Bigeminy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, Pocket</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1079"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="712"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="1079"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Hematoma, Pocket</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1079"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1079"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Adverse Reaction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1079"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Infection, Post Surgical</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1079"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <description>Secondary to use of contrast media</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1079"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Myocardial Perforation with Tamponade</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1079"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Arterial Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Venous Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Seroma, Pocket</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Pulse Generator Migration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Set Screws Not Tightened</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1079"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Post Surgical Wound Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1079"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="712"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="1079"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="712"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Extracardiac Stimulation, Left Ventricular</sub_title>
                <description>Events corrected non-invasively with reprogramming.</description>
                <counts group_id="E1" events="77" subjects_affected="70" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
              <event>
                <sub_title>Pacemaker Mediated Tachycardia</sub_title>
                <description>Events corrected non-invasively with reprogramming.</description>
                <counts group_id="E1" events="67" subjects_affected="56" subjects_at_risk="1079"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="712"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The FDA Circulatory Devices advisory panel recommended approval for the patient subpopulation with left bundle branch block (LBBB) only. Consequently, FDA has restricted indications for use to LBBB.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lisa Melchior</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>800 227 3422</phone>
      <email>lisa.melchior@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

